Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

The Effect of Glatiramer Acetate Therapy on Functional Properties of B Cells From Patients With Relapsing-Remitting Multiple Sclerosis.
Toxicity of Teriflunomide in Aryl Hydrocarbon Receptor Deficient Mice.
Altered likelihood of brain activation in attention and working memory networks in patients with multiple sclerosis: An ALE meta-analysis.
Receptos to deliver scientific presentations about RPC1063 at the 29th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS)
LETHAL MULTIPLE SCLEROSIS RELAPSE AFTER NATALIZUMAB WITHDRAWAL.
Cyclophosphamide
Impact of sleep disorder treatment on fatigue in multiple sclerosis.
Diffusely abnormal white matter in multiple sclerosis: further histologic studies provide evidence for a primary lipid abnormality with neurodegeneration.
Minocycline inhibits antigen processing for presentation to human T cells: additive inhibition with chloroquine at therapeutic concentrations.
Complexity of trophic factor signaling in experimental autoimmune encephalomyelitis: Differential expression of neurotrophic and gliotrophic factors.
Investigation of the mechanism of action of alemtuzumab in a human CD52 transgenic mouse model.
RILUTEK®
NQO1-dependent redox cycling of idebenone: effects on cellular redox potential and energy levels.
Arzerra
Effects of prophylactic and therapeutic teriflunomide in transcranial magnetic stimulation-induced motor-evoked potentials in the Dark Agouti rat model of experimental autoimmune encephalomyelitis.
Distinction and temporal stability of conformational epitopes on myelin oligodendrocyte glycoprotein recognized by patients with different inflammatory central nervous system diseases.
Trimesta in relapsing-remitting multiple sclerosis patients (Phase II)
Treatment Optimization in MS: Canadian MS Working Group Updated Recommendations.
Intrathecal Therapy With Monoclonal Antibodies in Progressive Multiple Sclerosis (ITT-PMS)
Pegylated interferon beta-1a for relapsing-remitting multiple sclerosis (ADVANCE): a randomised, phase 3, double-blind study.
ExtaviJect® 30G device for subcutaneous self-injection of interferon beta-1b for multiple sclerosis: a prospective European study.
Physicians from Accentia and Johns Hopkins University present plans for new MS drug study for Cyrevia
Epigenome-wide differences in pathology-free regions of multiple sclerosis-affected brains.
Varicella zoster-associated retinal and central nervous system vasculitis in a patient with multiple sclerosis treated with natalizumab.
Improved detection of cortical MS lesions with phase-sensitive inversion recovery MRI.

Pages